Riskpilot← Back to searchSign inGet full accessGB PHARMA ApS
APSActiveCVR 36054220Peder Hvitfeldts Stræde 12, st.Retail sale of cosmetic and toilet articles · NACE 4775Est. 20141 employees
Revenue 2024
DKK 42K
+91% vs 2023
EBITDA margin
76.9%
+162% vs 2023
Equity ratio
—
Financial strength
Net profit 2024
DKK -5K
+84% vs 2023
| Revenue | DKK 42K | +91% |
| EBITDA | DKK 33K | +162% |
| Net profit | DKK -5K | +84% |
| Total assets | DKK 0 | — |
| Equity | DKK -1,9M | +0% |
| Employees | 1 | — |
Legal name
GB PHARMA ApS
CVR number
36054220
Legal form
Anpartsselskab
NACE code
4775 · Retail sale of cosmetic and toilet articles
Founded
28. juli 2014
Share capital
DKK 50.000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes enten af en administrerende direktør, eller af bestyrelsens formand eller af den samlede bestyrelse.
Company purpose
Selskabets formål er direkte eller indirekte gennem ejerandele i andre virksomheder at drive virksomhed med marketing og salg af produkter indenfor sundhedsprodukter og kosmetik samt anden i forbindelse hermed værende virksomhed efter selskabets ledelses skøn.
Address
Peder Hvitfeldts Stræde 12, st.
Phone
+4533151410
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -1.071 | -426 | 9 | 43 | 47 | 0 | 0 | 43 | 22 | 42 |
| Staff expenses | -1.000 | -333 | -34 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -2.071 | -759 | 43 | 23 | 19 | -13 | -10 | 33 | 12 | 33 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -2.071 | -759 | 43 | 23 | 19 | -13 | -10 | 33 | 12 | 33 |
| Net financials | -26 | -19 | -55 | -40 | -38 | -37 | -38 | -40 | -43 | -38 |
| Profit before tax | -2.097 | -778 | -13 | -17 | -19 | -50 | -48 | -7 | -31 | -5 |
| Tax | -25 | -114 | -62 | -58 | -44 | -4 | -51 | -72 | -0 | -0 |
| Net profit | -2.072 | -664 | 50 | 41 | 25 | -46 | 3 | 65 | -31 | -5 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 26 | 204 | 64 | 73 | 44 | 4 | 51 | 72 | 0 | 0 |
| Equity | -2.022 | -2.687 | -1.987 | -1.945 | -1.921 | -1.966 | -1.964 | -1.899 | -1.930 | -1.934 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 2.049 | 2.890 | 2.051 | 2.019 | 1.965 | 1.970 | 2.015 | 1.971 | 1.930 | 1.934 |
| Total debt | 2.049 | 2.890 | 2.051 | 2.019 | 1.965 | 1.970 | 2.015 | 1.971 | 1.930 | 1.934 |
EBITDA margin
76.9%
This company
15.8%
Market median
+387% vs market
20152024
Equity ratio
-193445500.0%
This company
38.2%
Market median
-506401932% vs market
20152024
Return on equity
-494900.0%
This company
18.4%
Market median
-2689774% vs market
20152024
Net profit margin
-11.7%
This company
8.1%
Market median
-244% vs market
20152024
Asset turnover
42457.00×
This company
1.12×
Market median
+3790704% vs market
20152024
Debt / equity
1.00×
This company
0.62×
Market median
-61% vs market
20152024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2014-07-28 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
BR Chief Executive Officer | Chief Executive Officer | 2014 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2014 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of GB PHARMA ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Benny Roland Eriksen | Chief Executive Officer | 0 companies |